Superworth

Fortrea EPS FTRE

Diluted earnings per share by quarter and over the last twelve months, from 2022.

Last 12 months, to Jun 30, 2026
n/m
a quarter missing
Latest quarter, Q2 FY26
−$0.14
Fiscal year 2024
−$3.67

Fortrea's twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q2 FY26, it was −$0.14.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2024−$3.67n/a
FY2023−$0.28−113%
FY2022$2.18n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.14n/an/a
Q1 FY26−$0.25n/an/a
Q3 FY25−$0.17n/a−$11.24
Q2 FY25−$4.14n/a−$11.38
Q1 FY25−$6.25n/a−$8.79
Q4 FY24−$0.68n/a−$3.67
Q3 FY24−$0.31n/a−$3.60
Q2 FY24−$1.55−543%−$3.45
Q1 FY24−$1.13−907%−$1.55
Q4 FY23−$0.61−261%−$0.28
Q3 FY23−$0.16−124%$0.71
Q2 FY23$0.35−53%$1.55

Against its peers

Companies in Medical - Diagnostics & Research nearest Fortrea's size, closest first, today.

CompanyEPS, 12 monthsGrowth
FTREFortrean/m
CDNACareDx$2.07+116% a year
VCYTVeracyte$1.40+324% a year
BLLNBillionToOne$0.65
LNTHLantheus$4.13+10% a year
CAICaris Life Sciences$0.37
BIOBio-Rad Laboratories$8.25−30% a year
NRCNRC Health$0.25−67% a year
RVTYRevvity$2.10−11% a year
MEDPMedpace$17.05+27% a year
Peer median$2.07

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Fortrea

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.